Jean Francois Formela net worth and biography

Jean Formela Biography and Net Worth

Director of Korro Bio

Jean-François Formela, co-founder and board member of Korro Bio, is a partner at Atlas Venture and focuses on novel drug discovery approaches and therapeutics. He joined Atlas in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA) and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics.

Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL) and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François received his M.D. from Paris University School of Medicine and his MBA from Columbia University.

What is Jean Francois Formela's net worth?: The estimated net worth of Jean Francois Formela is at least $1.41 million as of August 26th, 2026. Formela owns 141,002 shares of Korro Bio stock worth more than $1,412,840 as of September 20th. This net worth evaluation does not reflect any other investments that Formela may own. Learn More about Jean Francois Formela's net worth.
How do I contact Jean Francois Formela?: The corporate mailing address for Formela and other Korro Bio executives is 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, 02141. Korro Bio can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Jean Francois Formela's contact information.
Has Jean Francois Formela been buying or selling shares of Korro Bio?: Over the course of the past ninety days, Jean Francois Formela has sold $1,975,626.36 in shares of Korro Bio stock. Most recently, Jean Francois Formela sold 300 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $13.96, for a transaction totalling $4,188.00. Following the completion of the sale, the director now directly owns 141,002 shares of the company's stock, valued at $1,968,387.92. Learn More on Jean Francois Formela's trading history.
Who are Korro Bio's active insiders?: Korro Bio's insider roster includes Ram Aiyar (Chief Executive Officer & President), Todd Chappell (Chief Operating Officer), Oliver Dolan (SVP), Jean Formela (Director), and Loïc Vincent (Chief Scientific Officer). Learn More on Korro Bio's active insiders.
Are insiders buying or selling shares of Korro Bio?: During the last twelve months, Korro Bio insiders bought shares 11 times. They purchased a total of 1,664,004 shares worth more than $18,491,374.58. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 344,295 shares worth more than $4,841,701.20. The most recent insider tranaction occured on September, 11th when SVP Oliver Dolan sold 5 shares worth more than $68.60. Insiders at Korro Bio own 4.8% of the company. Learn More about insider trades at Korro Bio.
Information on this page was last updated on 9/11/2026.

Jean Francois Formela Insider Trading History at Korro Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/26/2026	Sell	300	$13.96	$4,188.00	141,002
8/19/2026	Sell	28,468	$14.00	$398,552.00	141,053
8/11/2026	Sell	2,143	$13.96	$29,916.28	145,937
7/6/2026	Sell	9,323	$13.96	$130,149.08	146,305
7/2/2026	Sell	100,700	$14.03	$1,412,821.00	154,811
6/24/2026	Sell	48,438	$14.61	$707,679.18	169,556
6/23/2026	Sell	119,005	$14.25	$1,695,821.25	176,649
6/22/2026	Sell	3,962	$13.95	$55,269.90	194,075
5/28/2026	Sell	2,860	$13.95	$39,897.00	194,655

Jean Francois Formela Buying and Selling Activity at Korro Bio

Korro Bio Company Overview

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Today's Range

Now: $10.02

$9.51

$11.95

50 Day Range

MA: $12.45

$10.02

$14.07

2 Week Range

Now: $10.02

$5.20

$55.89

Volume

763,134 shs

Average Volume

123,454 shs

Market Capitalization

$147.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.09